Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia

[1]  I. Flinn,et al.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. , 2019, Blood.

[2]  H. Kantarjian,et al.  Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome , 2018, Hematological oncology.

[3]  U. Dührsen,et al.  FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia , 2018, Leukemia & lymphoma.

[4]  R. Schlenk,et al.  Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia , 2018, British journal of haematology.

[5]  Guolin Yuan,et al.  Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia , 2018, Acta Haematologica.

[6]  D. Pollyea.  New drugs for acute myeloid leukemia inspired by genomics and when to use them. , 2018, Hematology. American Society of Hematology. Education Program.

[7]  L. Michaelis.  Cytotoxic therapy in acute myeloid leukemia: not quite dead yet. , 2018, Hematology. American Society of Hematology. Education Program.

[8]  G. Ledderose,et al.  Sequential HLA‐haploidentical transplantation utilizing post‐transplantation cyclophosphamide for GvHD prophylaxis in high‐risk and relapsed/refractory AML/MDS , 2018, American journal of hematology.

[9]  T. Naoe,et al.  Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study , 2018, Cancer science.

[10]  Chunsen Wang,et al.  A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia , 2018, Cellular Physiology and Biochemistry.

[11]  Jiang Liu,et al.  FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. , 2018, The oncologist.

[12]  G. Marcucci,et al.  Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia , 2018, Haematologica.

[13]  B. Jonas,et al.  New and emerging therapies for acute myeloid leukaemia , 2018, Journal of Investigative Medicine.

[14]  B. Leber,et al.  A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. , 2018, Blood advances.

[15]  H. Kantarjian,et al.  Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. , 2018, Blood.

[16]  Depei Wu,et al.  Efficacy of haploidentical hematopoietic stem cell transplantation compared to HLA-matched transplantation for primary refractory acute myeloid leukemia , 2018, Annals of Hematology.

[17]  E. Estey,et al.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.

[18]  T. Owa,et al.  Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome , 2018, Cancer.

[19]  P. Sharma,et al.  Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes , 2018, Leukemia.

[20]  K. Messer,et al.  A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia , 2018, Clinical lymphoma, myeloma & leukemia.

[21]  S. Agaugué,et al.  NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient , 2018, Haematologica.

[22]  Tae Kon Kim,et al.  Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. , 2018, Blood advances.

[23]  M. Sanz,et al.  Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review , 2018, Annals of Hematology.

[24]  Fan Yang,et al.  A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia , 2018, Medicine.

[25]  G. Lenz,et al.  High‐dose melphalan‐based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia , 2018, British journal of haematology.

[26]  L. Miller,et al.  A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia , 2018, Clinical Cancer Research.

[27]  M. Amiot,et al.  Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. , 2017, Blood.

[28]  Y. Bao,et al.  Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study , 2017, Clinical and Translational Oncology.

[29]  T. Kidokoro,et al.  Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. , 2017, Blood.

[30]  Hong Wang,et al.  Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. , 2017, Cytotherapy.

[31]  S. Mabuchi,et al.  PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo. , 2017, Immunotherapy.

[32]  P. Allavena,et al.  Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models , 2017, British Journal of Cancer.

[33]  R. Larson,et al.  Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study , 2017, The Lancet. Oncology.

[34]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[35]  M. Caligiuri,et al.  A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485 , 2017, Haematologica.

[36]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[37]  M. Levis,et al.  Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. , 2017, Blood.

[38]  Steven M. Chan,et al.  Isocitrate dehydrogenase mutations in myeloid malignancies , 2016, Leukemia.

[39]  S. de Botton,et al.  IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives , 2016, Journal of blood medicine.

[40]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[41]  M. Caligiuri,et al.  Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. , 2016, Blood.

[42]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[43]  H. Ljunggren,et al.  Emerging insights into natural killer cells in human peripheral tissues , 2016, Nature Reviews Immunology.

[44]  K. Yen,et al.  IDH mutations in cancer and progress toward development of targeted therapeutics. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  Asim Khwaja,et al.  Acute myeloid leukaemia , 2016, Nature Reviews Disease Primers.

[46]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[47]  Yue-zhong Wu,et al.  Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia , 2016, Leukemia & lymphoma.

[48]  B. Dörken,et al.  Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long‐term outcome , 2015, European journal of haematology.

[49]  R. Schlenk,et al.  How I treat refractory and early relapsed acute myeloid leukemia. , 2015, Blood.

[50]  Ya-Zhen Qin,et al.  Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[51]  R. Childs,et al.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens , 2015, Nature Reviews Drug Discovery.

[52]  M. Levis,et al.  Inhibition of c-Kit by tyrosine kinase inhibitors , 2015, Haematologica.

[53]  Bob Löwenberg,et al.  Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center , 2014, Leukemia.

[54]  Quan-shun Wang,et al.  Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  M. Gobbi,et al.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[56]  M. Konopleva,et al.  Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations , 2014, Cancer.

[57]  M. Andreeff,et al.  Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia , 2014, Expert opinion on investigational drugs.

[58]  P. Bingham,et al.  A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process , 2014, Cancer & metabolism.

[59]  I. Weissman,et al.  Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission , 2014, Proceedings of the National Academy of Sciences.

[60]  R. Vij,et al.  Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML , 2014, International Journal of Hematology.

[61]  James M. Bogenberger,et al.  BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies , 2014, Leukemia.

[62]  S. Parmar,et al.  Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents , 2013, Leukemia.

[63]  M. Levis.  FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? , 2013, Hematology. American Society of Hematology. Education Program.

[64]  A. Scott,et al.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  Peter A. Jones,et al.  Alterations of immune response of non-small cell lung cancer with Azacytidine , 2013, Oncotarget.

[66]  H. Kantarjian,et al.  Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[68]  S. Gasser,et al.  Regulation of ligands for the NKG2D activating receptor. , 2013, Annual review of immunology.

[69]  J. Rowe,et al.  The myth of the second remission of acute leukemia in the adult. , 2013, Blood.

[70]  K. Götze,et al.  High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses , 2012, Leukemia.

[71]  T. Raum,et al.  Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses , 2012, The Journal of Immunology.

[72]  B. Leber,et al.  Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells , 2012, Cell.

[73]  S. Lok,et al.  Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. , 2012, Blood.

[74]  Andrew Kasarskis,et al.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.

[75]  Keith Abrams,et al.  Use of Indirect and Mixed Treatment Comparisons for Technology Assessment , 2012, PharmacoEconomics.

[76]  R. Vij,et al.  A phase 1 / 2 study of chemosensitization with the CXCR 4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia , 2012 .

[77]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[78]  P. Bingham,et al.  Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo , 2011, Journal of Molecular Medicine.

[79]  W. Wiktor-Jedrzejczak,et al.  Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. , 2011, Blood.

[80]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[81]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  P. Zarrinkar,et al.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). , 2009, Blood.

[83]  Julie L Prior,et al.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. , 2009, Blood.

[84]  G. Adolf,et al.  BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity , 2009, Clinical Cancer Research.

[85]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[86]  M. Caligiuri,et al.  The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. , 2008, Blood.

[87]  Jeroen P Jansen,et al.  Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[88]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[89]  M. Caligiuri,et al.  Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. , 2006, The Journal of clinical investigation.

[90]  W. Hiddemann,et al.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.

[91]  J. Kell.  Treatment of relapsed acute myeloid leukaemia. , 2006, Reviews on recent clinical trials.

[92]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  J. Lipton,et al.  Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? , 2005, Bone Marrow Transplantation.

[94]  C. Kalberer,et al.  Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. , 2005, Blood.

[95]  Christie M. Orschell,et al.  Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist , 2005, The Journal of experimental medicine.

[96]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[97]  F. Meng,et al.  [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia]. , 2004, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA.

[98]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[99]  O. Haas,et al.  Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse , 2004, Leukemia.

[100]  X. Thomas,et al.  Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. , 2003, Leukemia research.

[101]  W. Hiddemann,et al.  Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy , 2002, Leukemia.

[102]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[103]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[104]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[105]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[106]  D. Neuberg,et al.  Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate‐dose cytarabine , 2000, Cancer.

[107]  P. Campochiaro,et al.  PKC412--a protein kinase inhibitor with a broad therapeutic potential. , 2000, Anti-cancer drug design.

[108]  R. Gray,et al.  A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.

[109]  T. Owa,et al.  Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. , 1999, Journal of medicinal chemistry.

[110]  F. Ferrara,et al.  Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation , 1999, Annals of Hematology.

[111]  P. Steinherz,et al.  Antileukemia activity of a natural killer cell line against human leukemias. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[112]  H. Saito,et al.  Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product , 1998, Leukemia.

[113]  W. Hiddemann,et al.  Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison , 1998, Leukemia.

[114]  G Mele,et al.  Fludarabine, cytarabine, and G‐CSF (FLAG) for the treatment of poor risk acute myeloid leukemia , 1998, American journal of hematology.

[115]  M. Caligiuri,et al.  Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. , 1998, Cancer research.

[116]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens , 1997, International journal of cancer.

[117]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[118]  K. Laczika,et al.  Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study , 1996, Annals of Hematology.

[119]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[120]  P. Zinzani,et al.  FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. , 1994, Leukemia.

[121]  J. Sakamoto,et al.  Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma. , 1993, The American journal of gastroenterology.

[122]  E. Estey,et al.  Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. , 1993, Leukemia & lymphoma.

[123]  E. Estey,et al.  Response to salvage therapy and survival after relapse in acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  R. Willemze,et al.  Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. , 1989, Blood.

[125]  R. Gray,et al.  PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.

[126]  C. Cordon-Cardo,et al.  Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. , 1986, Cancer research.